Startseite
Français
Deutsch
English
linkedin  facebook  

Tamoxifen (Pharmacogenetics)

A PHARMAgen product

Tamoxifen is a widely used treatment for breast cancer. Tamoxifen is a prodrug, which is converted into the active metabolite endoxifen by the CYP2D6 enzyme. In the case of a reduced or absent activation of the drug, which can be identified by CYP2D6 genotyping, a possible poor outcome of a tamoxifen therapy can be avoided by choosing an alternative treatment method, such as the administration of aromatase inhibitors.

Downloads

Brochure
Size:3 MB
Consent Form
Size:500 KBytes
Order Form
Size:500 KBytes